- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Harris & Harris Group, Inc. (NASDAQ: TINY), an early-stage, active investor in transformative nanotechnology companies, notes an article by Andrew Pollack in the front page of The New York Times, dated September 26, 2012, titled "Seeking Cures, Patients Enlist Mice Stand-Ins."
The article focuses on advances in personalized medicine made possible by the ability for mice to bear human cancers and serve as "avatars" for testing drugs on human cancers. The article highlights work performed by Champions Oncology, Inc., a Harris & Harris Group portfolio company. The article may be accessed at www.nytimes.com/2012/09/26/business/mice-as-stand-ins-in-the-fight-against-disease.html?ref=todayspaper.
About Harris & Harris Group, Inc.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.nytimes.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
For more information, please click here
Copyright © Harris & Harris Group, Inc.If you have a comment, please Contact us.
|Related News Press|
News and information
Chivalrous Knight Does Pro Bono June 27th, 2015
Exagan Raises €5.7 Million to Produce High-efficiency GaN-on-Silicon Power-switching Devices on 200mm Wafers: Leti-and-Soitec Spinout Focused on Becoming Leading European Source Of GaN Devices for Solar, Automotive, Telecoms and Infrastructure June 25th, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015